COLOMBO NICOLETTA

Riva, C., Minetto, P., Chies, M., Vernarecci, C., Colombo, N., Rosellini, S., et al. (2025). Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease. HEMATOLOGICAL ONCOLOGY, 43(1 (January 2025)) [10.1002/hon.70005]. Detail

Scambia, G., Villalobos Valencia, R., Colombo, N., Cibula, D., Leath, C., Bidziński, M., et al. (2025). Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results. JOURNAL OF CLINICAL ONCOLOGY, 43(12) [10.1200/JCO.24.00933]. Detail

Grisham, R., Monk, B., Van Nieuwenhuysen, E., Moore, K., Fabbro, M., O'Malley, D., et al. (2025). GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER [10.1136/ijgc-2024-005919]. Detail

De Vitis, L., Schivardi, G., Gaeta, A., Caruso, G., Rosanu, M., Ribero, L., et al. (2025). External validation of the Annual Recurrence Risk Model (ARRM) for tailored surveillance strategy in patients with cervical cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER [10.1016/j.ijgc.2025.101756]. Detail

Lorusso, D., Colombo, N., Dubot, C., Cáceres, M., Hasegawa, K., Shapira-Frommer, R., et al. (2025). Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study. ANNALS OF ONCOLOGY, 36(1), 65-75 [10.1016/j.annonc.2024.10.002]. Detail